Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML3316

Sigma-Aldrich

TQS

≥98% (HPLC)

Synonym(s):

3a,4,5,9b-Tetrahydro-4-(1-naphthalenyl)-3H-cyclopenta[c]quinoline-8-sulfonamide

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
$151.00
25 MG
$610.00

$151.00

Estimated to ship on11 April 2025

All Photos(1)

Select a Size

Change View
5 MG
$151.00
25 MG
$610.00

About This Item

Empirical Formula (Hill Notation):
C22H20N2O2S
CAS Number:
353483-92-8
Molecular Weight:
376.47
MDL number:
MFCD01080566
UNSPSC Code:
12352200
NACRES:
NA.77

$151.00

Estimated to ship on11 April 2025

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

NS(C1=CC2=C(NC(C3=CC=CC4=C3C=CC=C4)C5C2C=CC5)C=C1)(=O)=O

InChI

1S/C22H20N2O2S/c23-27(25,26)15-11-12-21-20(13-15)17-8-4-10-19(17)22(24-21)18-9-3-6-14-5-1-2-7-16(14)18/h1-9,11-13,17,19,22,24H,10H2,(H2,23,25,26)

InChI key

SIZWDJIHABLBSP-UHFFFAOYSA-N

Biochem/physiol Actions

α7nAChR positive allosteric modulator
TQS is a type-II positive allosteric modulator of α7 nAChR. TQS potentiates agonist-invoked responses, and dramatically reduces the rate of desensitization of α7 nAChR. The compound has no agonist activity alone. The EC50 for potentiation of submaximal doses of acetylcholine is 6.2µM.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000162926
0000174869
0000174871

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marta Quadri et al.
The Journal of pharmacology and experimental therapeutics, 367(2), 203-214 (2018-08-17)
Chronic pain and inflammatory diseases can be regulated by complex mechanisms involving α7 nicotinic acetylcholine receptors (nAChRs), making this subtype a promising drug target for anti-inflammatory therapies. Recent evidence suggests that suchtreatment of inflammatory pain may rely on metabotropic-like rather
Jaskiran K Gill et al.
Proceedings of the National Academy of Sciences of the United States of America, 108(14), 5867-5872 (2011-03-26)
Conventional nicotinic acetylcholine receptor (nAChR) agonists, such as acetylcholine, act at an extracellular "orthosteric" binding site located at the interface between two adjacent subunits. Here, we present evidence of potent activation of α7 nAChRs via an allosteric transmembrane site. Previous
Jens Halvard Grønlien et al.
Molecular pharmacology, 72(3), 715-724 (2007-06-15)
Selective modulation of alpha7 nicotinic acetylcholine receptors (nAChRs) is thought to regulate processes impaired in schizophrenia, Alzheimer's disease, and other dementias. One approach to target alpha7 nAChRs is by positive allosteric modulation. Structurally diverse compounds, including PNU-120596, 4-naphthalene-1-yl-3a,4,5,9b-tetrahydro-3-H-cyclopenta[c]quinoline-8-sulfonic acid amide

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service